|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
2009-11-5
|
|
pubmed:abstractText |
CD8(+) natural killer T (NKT) cells from EBV-associated tumour patients are quantitatively and functionally impaired. EBV-induced CD8(+) NKT cells drive syngeneic T cells into a Th1-bias response to suppress EBV-associated malignancies. IL-4-biased CD4(+) NKT cells do not affect either syngeneic T cell cytotoxicity or Th cytokine secretion. Circulating mDC1 cells from patients with EBV-associated malignancies impair the production of IFN-gamma by CD8(+) NKT cells. In this study, we have established a human-thymus-SCID chimaera model to further investigate the underlying mechanism of EBV-induced CD8(+) NKT cells in suppressing EBV-associated malignancies. In the human-thymus-SCID chimera, EBV-induced CD8(+) NKT cells suppress EBV-associated malignancies in a manner dependent on the Th1-bias response and syngeneic CD3(+) T cells. However, adoptive transfer with CD4(+) NKT cells alone inhibits T cell immunity. Interestingly, CD4(+) NKT cells themselves secrete high levels of IL-2, enhancing the persistence of adoptively transferred CD8(+) NKT cells and T cells, thereby leading to a more pronounced T cell anti-tumour response in chimaeras co-transferred with CD4(+) and CD8(+) NKT cells. Thus, immune reconstitution with EBV-induced CD4(+) and CD8(+) NKT cells synergistically enhances T cell tumour immunity, providing a potential prophylactic and therapeutic treatment for EBV-associated malignancies.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
2042-0226
|
|
pubmed:author |
pubmed-author:HeYulingY,
pubmed-author:HuangWeiW,
pubmed-author:JiXiangX,
pubmed-author:JinYouxinY,
pubmed-author:JinquanTanT,
pubmed-author:LangChenC,
pubmed-author:MengjunWuW,
pubmed-author:RuijingXiaoX,
pubmed-author:VogtBB,
pubmed-author:WangLanL,
pubmed-author:WangYujuanY,
pubmed-author:XXX,
pubmed-author:XintiTanT,
pubmed-author:XiongJieJ,
pubmed-author:XiongTaoT,
pubmed-author:ZhengXiaolingX,
pubmed-author:ZhouRuiR
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
6
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
367-79
|
|
pubmed:dateRevised |
2011-8-19
|
|
pubmed:meshHeading |
pubmed-meshheading:19887050-Adoptive Transfer,
pubmed-meshheading:19887050-Animals,
pubmed-meshheading:19887050-Antigens, CD4,
pubmed-meshheading:19887050-Antigens, CD8,
pubmed-meshheading:19887050-Cell Line, Tumor,
pubmed-meshheading:19887050-Chimera,
pubmed-meshheading:19887050-Cytotoxicity, Immunologic,
pubmed-meshheading:19887050-Epstein-Barr Virus Infections,
pubmed-meshheading:19887050-Herpesvirus 4, Human,
pubmed-meshheading:19887050-Hodgkin Disease,
pubmed-meshheading:19887050-Humans,
pubmed-meshheading:19887050-Interferon-gamma,
pubmed-meshheading:19887050-Interleukin-2,
pubmed-meshheading:19887050-Interleukin-4,
pubmed-meshheading:19887050-Lymphocyte Activation,
pubmed-meshheading:19887050-Lymphoma, B-Cell,
pubmed-meshheading:19887050-Mice,
pubmed-meshheading:19887050-Mice, SCID,
pubmed-meshheading:19887050-Nasopharyngeal Neoplasms,
pubmed-meshheading:19887050-Natural Killer T-Cells,
pubmed-meshheading:19887050-T-Lymphocyte Subsets,
pubmed-meshheading:19887050-Th1 Cells
|
|
pubmed:year |
2009
|
|
pubmed:articleTitle |
EBV-induced human CD8(+) NKT cells synergise CD4(+) NKT cells suppressing EBV-associated tumours upon induction of Th1-bias.
|
|
pubmed:affiliation |
Laboratory of Allergy and Clinical Immunology, Institute of Allergy and Immune-related Diseases, Center for Medical Research, and Department of Immunology, Wuhan University School of Medicine, Wuhan, China.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
